3-cyclohexyl-5-methyl-isoxazole-4-carboxylic acid ethyl ester | 1144506-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-cyclohexyl-5-methyl-isoxazole-4-carboxylic acid ethyl ester
• 英文别名: Ethyl 3-cyclohexyl-5-methyl-1,2-oxazole-4-carboxylate
• CAS: 1144506-35-3
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.299
• InChiKey: LBERNHZZRUIDOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 氧气 作用下， 以95%的产率得到3-cyclohexyl-5-methyl-isoxazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  A convenient synthesis of functionalized isoxazolines and related 5-hydroxyisoxazolidine-4-carboxylates

  摘要：

  The effectiveness of Sc(OTf)(3) as a Lewis acid catalyst for the 1,4-addition reaction of carbamates to appropriate 2-acetyl-2-pentenoic esters is herein reported. In particular, N-benzyl-(tert-butyldimethyl-silyloxy)carbamate added efficiently to the title substrates to afford a new class of polyfunctionalized isoxazolidines and isoxazolines. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.01.071

文献信息

• [EN] ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS<br/>[FR] DÉRIVÉS D'ISOXAZOLE-PYRIDINE EN TANT QUE MODULATEURS DE GABA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010127978A1

  公开（公告）日：2010-11-11

  The present invention is concerned with novel isoxazole derivatives of formula (I) wherein X, R1, R2, R3 and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula (I), pharmaceutical compositions containing them and their use as medicaments.

  本发明涉及具有以下式（I）的新异恶唑衍生物，其中X、R1、R2、R3和R4如本文所述，以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外，本发明涉及制备具有式（I）的活性化合物、含有它们的药物组合物以及它们作为药物的用途。
• PYRIDINES
  申请人：Buettelmann Bernd

  公开号：US20100286117A1

  公开（公告）日：2010-11-11

  The present invention is concerned with novel isoxazoles of formula I wherein X, R 1 , R 2 , R 3 and R 4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as therapeutics.

  本发明涉及公式I的新型异噁唑，其中X，R1，R2，R3和R4如本文所述，以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外，本发明还涉及制造公式I的活性化合物，含有它们的药物组合物以及它们作为治疗药物的用途。
• ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2427457A1

  公开（公告）日：2012-03-14
• US8357703B2
  申请人：——

  公开号：US8357703B2

  公开（公告）日：2013-01-22